Granted Patent B2

US 12,527,798 · App. 18/072,963 · Granted Jan 20, 2026

Inventors: Jessica A. Sorrentino (Durham, NC); Anne Y. Lai (Cary, NC); Jay C. Strum (Hillsborough, NC); Patrick Joseph Roberts (Durham, NC)

Assignee: Pharmacosmos Holding A/S

A61K31/519A61K31/365A61K33/243A61K38/1774A61P35/00

Abstract

Claims (35)

1 . A method of treating a human having cancer comprising administering to the human a therapeutic regimen comprising a) an induction phase and b) a maintenance phase,

a) the induction phase comprising:

i) administering to the human an effective amount of a selective Cyclin Dependent Kinase 4/6 (CDK4/6) inhibitor having the structure:

or a pharmaceutically acceptable salt thereof,

ii) administering to the human an effective amount of a chemotherapeutic agent, and

iii) administering to the human an effective amount of an immune checkpoint inhibitor, wherein, during the induction phase, the CDK4/6 inhibitor is only administered 2 hours or less prior to the administration of the chemotherapeutic agent, and wherein the chemotherapeutic agent is cytotoxic to immune effector cells;

b) the maintenance phase comprising:

i) administering to the human at least one dose of an effective amount of the immune checkpoint inhibitor, and wherein the maintenance phase is administered following the cessation of the induction phase.

2 . The method of claim 1 , wherein the immune checkpoint inhibitor is selected from the group consisting of a Programmed Cell Death-1 (PD-1) inhibitor, a Programmed Cell Death-Ligand 1 (PD-L1) inhibitor, and a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor.

3 . The method of claim 2 , wherein the immune checkpoint inhibitor is a PD-L1 inhibitor.

4 . The method of claim 3 , wherein the PD-L1 inhibitor is selected from the group consisting of atezolizumab, avelumab, and durvalumab.

5 . The method of claim 2 , wherein the immune checkpoint inhibitor is a PD-1 inhibitor.

6 . The method of claim 5 , wherein the PD-1 inhibitor is selected from the group consisting of nivolumab, pidilizumab, and pembrolizumab.

7 . The method of claim 2 , wherein the immune checkpoint inhibitor is a CTLA-4 inhibitor.

8 . The method of claim 7 , wherein the CTLA-4 inhibitor is selected from the group consisting of ipilimumab and tremelimumab.

9 . The method of claim 4 , wherein the chemotherapeutic agent is selected from the group consisting of a protein synthesis inhibitor, a DNA-damaging chemotherapeutic, an akylating agent, a topoisomerase inhibitor, an RNA synthesis inhibitor, a DNA complex binder, a thiolate alkylating agent, a guanine alkylating agent, a tubulin binder, a DNA polymerase inhibitor, an anticancer enzyme, a RAC 1 inhibitor, a thymidylate synthase inhibitor, an oxazophosphorine compound, an integrin inhibitor, an antifolate, a folate antimetabolite, and a combination thereof.

10 . The method of claim 9 , wherein the chemotherapeutic agent is selected from the group consisting of carboplatin, cisplatin, oxaliplatin, 5-fluorouracil, floxuridine, capecitabine, gemcitabine, mitomycin C, cyclophosphamide, dacarbazine, abraxane, ifosfamide, topotecan, irinotecan, docetaxel, temozolomide, paclitaxel, etoposide, pemetrexed, and a combination thereof.

11 . The method of claim 10 , wherein the chemotherapeutic agent is selected from the group consisting of carboplatin, cisplatin, etoposide, and a combination thereof.

12 . The method of claim 11 , wherein the chemotherapeutic agent is selected from the group consisting of a combination of carboplatin and etoposide and a combination of cisplatin and etoposide.

13 . The method of claim 12 , wherein the cancer is selected from the group consisting of small cell lung cancer, non-small cell lung cancer, triple negative breast cancer, colorectal cancer, ovarian cancer, pancreatic cancer, bladder cancer, gastroesophageal cancer, cholangiocarcinoma, cervical cancer, and soft tissue sarcoma.

14 . The method of claim 13 , wherein the cancer is small cell lung cancer.

15 . A method of treating a human having small cell lung cancer comprising administering to the human a therapeutic regimen comprising a) an induction phase and b) a maintenance phase,

a) the induction phase comprising:

i) administering to the human an effective amount of a selective Cyclin Dependent Kinase 4/6 (CDK4/6) inhibitor having the structure:

or a pharmaceutically acceptable salt thereof,

ii) administering to the human an effective amount of a chemotherapeutic agent selected from the group consisting of a combination of carboplatin and etoposide and a combination of cisplatin and etoposide, and

iii) administering to the human an effective amount of a PD-L1 inhibitor selected from the group consisting of atezolizumab, avelumab, and durvalumab,

wherein, during the induction phase, the CDK4/6 inhibitor is only administered 4 hours or less prior to the administration of the chemotherapeutic agent, and

b) the maintenance phase comprising:

i) administering to the human at least one dose of an effective amount of the PD-L1 inhibitor, and

wherein the maintenance phase is administered following the cessation of the induction phase.

16 . The method of claim 15 , wherein the chemotherapeutic agent is a combination of carboplatin and etoposide.

17 . The method of claim 15 , wherein the chemotherapeutic agent is a combination of cisplatin and etoposide.

18 . The method of claim 15 , wherein the PD-L1 inhibitor is atezolizumab.

19 . The method of claim 15 , wherein the chemotherapeutic agent is a combination of carboplatin and etoposide, and the PD-L 1 inhibitor is atezolizumab.

Assignments (5)

Continuity (5)

References Cited (241)